AMP Capital Investors Ltd raised its position in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) by 6.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 142,910 shares of the specialty pharmaceutical company’s stock after acquiring an additional 8,484 shares during the quarter. AMP Capital Investors Ltd’s holdings in Valeant Pharmaceuticals International were worth $2,043,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP boosted its stake in shares of Valeant Pharmaceuticals International by 327.6% during the 3rd quarter. Dimensional Fund Advisors LP now owns 4,472,185 shares of the specialty pharmaceutical company’s stock valued at $64,086,000 after purchasing an additional 3,426,410 shares in the last quarter. Paulson & CO. Inc. boosted its stake in shares of Valeant Pharmaceuticals International by 12.5% during the 2nd quarter. Paulson & CO. Inc. now owns 21,813,400 shares of the specialty pharmaceutical company’s stock valued at $377,372,000 after purchasing an additional 2,428,900 shares in the last quarter. Renaissance Technologies LLC bought a new stake in shares of Valeant Pharmaceuticals International during the 2nd quarter valued at about $41,574,000. Cannell Peter B & Co. Inc. bought a new stake in shares of Valeant Pharmaceuticals International during the 2nd quarter valued at about $20,981,000. Finally, Beach Point Capital Management LP bought a new stake in shares of Valeant Pharmaceuticals International during the 3rd quarter valued at about $15,670,000. Hedge funds and other institutional investors own 49.45% of the company’s stock.

In other Valeant Pharmaceuticals International news, Director John Paulson acquired 344,216 shares of the company’s stock in a transaction that occurred on Thursday, November 16th. The shares were acquired at an average price of $14.40 per share, with a total value of $4,956,710.40. Following the completion of the purchase, the director now directly owns 94,559 shares of the company’s stock, valued at approximately $1,361,649.60. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 5.87% of the company’s stock.

Shares of Valeant Pharmaceuticals International, Inc. (VRX) opened at $20.86 on Wednesday. Valeant Pharmaceuticals International, Inc. has a 52 week low of $8.31 and a 52 week high of $22.81. The company has a debt-to-equity ratio of 4.84, a quick ratio of 1.03 and a current ratio of 1.26. The company has a market cap of $7,390.15, a PE ratio of 3.45, a P/E/G ratio of 0.58 and a beta of -0.22.

VRX has been the topic of a number of research reports. Cantor Fitzgerald set a $23.00 target price on shares of Valeant Pharmaceuticals International and gave the company a “buy” rating in a research note on Tuesday, October 31st. Piper Jaffray Companies reaffirmed a “sell” rating and set a $12.00 target price on shares of Valeant Pharmaceuticals International in a research note on Friday, November 10th. Vetr raised shares of Valeant Pharmaceuticals International from a “buy” rating to a “strong-buy” rating and set a $19.72 target price on the stock in a research note on Tuesday, December 5th. TD Securities raised shares of Valeant Pharmaceuticals International from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a research note on Tuesday, November 7th. Finally, ValuEngine raised shares of Valeant Pharmaceuticals International from a “hold” rating to a “buy” rating in a research note on Tuesday, December 12th. Six analysts have rated the stock with a sell rating, ten have given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $17.72.

ILLEGAL ACTIVITY WARNING: “AMP Capital Investors Ltd Has $2.04 Million Holdings in Valeant Pharmaceuticals International, Inc. (VRX)” was first reported by Watch List News and is owned by of Watch List News. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://www.watchlistnews.com/amp-capital-investors-ltd-has-2-04-million-holdings-in-valeant-pharmaceuticals-international-inc-vrx/1774495.html.

Valeant Pharmaceuticals International Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Want to see what other hedge funds are holding VRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX).

Institutional Ownership by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.